Spots Global Cancer Trial Database for Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

Official Title: INST 0817: Compassionate Use of Mifepristone

Study ID: NCT00832871

Conditions

Cancer

Interventions

Mifepristone

Study Description

Brief Summary: The purpose of this study is to see if mifepristone prevents worsening of your cancer. Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is commonly used for the termination of pregnancies. It has not been approved by the Food and Drug Administration for use in the treatment of cancer. It is unlicensed in the United States for your condition. However, previous work has indicated that mifepristone may be useful due to how it works. It is being made available for use in the United States for compassionate use through the Feminist Majority Foundation.

Detailed Description: This is a compassionate use of mifepristone treatment for patients with conditions that could respond to an antiprogesterone agent, including: * Meningioma. * Breast cancer * Colon Cancer * Endometrial Stromal Sarcoma * Bilateral Chronic Central Serous Retinopathy * Cushing's Syndrome * Metastatic Adrenocortical Cancer * Ovarian Cancer * Other conditions as determined by the attending physicians